Sutton Wealth Advisors Inc. Supernus Pharmaceuticals, Inc. Transaction History

Sutton Wealth Advisors Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$34.93 - $42.03 $24,870 - $29,925	-712 Closed	0 $0
Q2 2022 Nov 07, 2023	SELL	$25.33 - $34.25 $4,230 - $5,719	-167 Reduced 19.0%	712 $20.6 Million
Q1 2022 Nov 07, 2023	BUY	$28.51 - $32.9 $570 - $658	20 Added 2.33%	879 $28.4 Million
Q4 2021 Nov 07, 2023	BUY	$26.37 - $34.22 $4,087 - $5,304	155 Added 22.02%	859 $25 Million
Q1 2020 Nov 07, 2023	SELL	$14.45 - $24.69 $505 - $864	-35 Reduced 4.74%	704 $12.7 Million
Q4 2019 Nov 07, 2023	BUY	$19.93 - $29.13 $697 - $1,019	35 Added 4.97%	739 $17.5 Million
Q1 2019 Nov 06, 2023	SELL	$32.77 - $41.99 $2,687 - $3,443	-82 Reduced 10.43%	704 $24.7 Million
Q4 2018 Nov 06, 2023	BUY	$30.84 - $49.51 $2,528 - $4,059	82 Added 11.65%	786 $26.1 Million
Q1 2016 Nov 06, 2023	BUY	N/A	704	704 $10.7 Million

283

60.8M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.